The objective of this study is to collect information on patients with cardiomyopathy (CM) due to mutations in the MYBPC3 gene, to evaluate their disease course, burden of illness, risk factors for this disease, and the quality of life (QoL). This study will also collect information on treatments, procedures and outcome in infants and children up to 18 yrs who have this mutation.
Cardiomyopathy
The objective of this study is to collect information on patients with cardiomyopathy (CM) due to mutations in the MYBPC3 gene, to evaluate their disease course, burden of illness, risk factors for this disease, and the quality of life (QoL). This study will also collect information on treatments, procedures and outcome in infants and children up to 18 yrs who have this mutation.
Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy
-
Arkansas Children's Hospital, Little Rock, Arkansas, United States, 72202
Children's Hospital Los Angeles, Los Angeles, California, United States, 90027
University of California Davis Health, Sacramento, California, United States, 95817
Rady Children's Hospital - San Diego, San Diego, California, United States, 92123
University of Colorado Hospital - Anschutz Medical Campus, Aurora, Colorado, United States, 80045
Nemours Alfred I. Dupont Hospital for Children, Wilmington, Delaware, United States, 19803
Joe DiMaggio Children's Hospital, Hollywood, Florida, United States, 33021
Children's Mercy Hospital Kansas, Kansas City, Missouri, United States, 64108
St. Louis Children's Hospital, Saint Louis, Missouri, United States, 63110
Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States, 10467
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
0 Years to 18 Years
ALL
No
Tenaya Therapeutics,
2028-06